RYTM

Insider trade Sale by German Christopher Paul (Corporate Controller & CAO)

13d ago

News New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data

14d ago

News Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

14d ago

News Green Thumb Just Made an Unprecedented Move. Here's What It Means for GTBIF Investors.

19d ago

SEC filing RYTM Announces FDA Approval of IMCIVREE for Acquired HO, -18.4% BMI Reduction in Phase 3, Conference Call 7PM ET

74d ago

News Rhythm Pharma higher after FDA label expansion for lead drug

74d ago

News Rhythm Pharma down after late-stage trial setback for lead asset in rare obesity disorders

77d ago

News Catalyst Watch: Nvidia's GTC Conference, FOMC meeting, Okta event, and triple-witching day

80d ago

Insider trade Sale by Christopher Paul German (Corporate Controller & CAO)

87d ago

News Rhythm anticipates $385M–$415M in 2026 non-GAAP operating expenses as HO launch preparations accelerate

95d ago

Insider trade Sale by Hunter C Smith (Chief Financial Officer)

104d ago

Insider trade Sale by Hunter C Smith (Chief Financial Officer)

104d ago

News Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise

153d ago

Scanner Unusual volume (z=7.3)

171d ago